OneMedNet Corp - ONMD STOCK NEWS

OneMedNet (ONMD) has received a notice from Nasdaq due to failing to file its Form 10-Q for Q3 2024 on time. This follows previous delays in filing Q1 and Q2 2024 reports. Nasdaq had granted an exception until December 11, 2024, to file these delinquent quarterly reports. The company must submit an updated compliance plan by December 6, 2024. While working to complete these filings, OneMedNet's stock and warrants continue to trade on The Nasdaq Capital Market. However, there's no guarantee the company will regain or maintain compliance with Nasdaq listing requirements.

OneMedNet (Nasdaq: ONMD), a pioneer in curating regulatory-grade Real World Data (RWD), has announced an additional strategic investment in Bitcoin. As of November 12, 2024, the company has acquired approximately 34 Bitcoin. The investment aims to enhance financial resilience and support the expansion of their iRWD™ platform. Off The Chain Capital, a significant investor in OneMedNet, has provided expertise regarding Bitcoin investments. The company's Bitcoin strategy follows the approach pioneered by Michael Saylor and MicroStrategy.

OneMedNet (Nasdaq: ONMD), a leading curator of regulatory-grade Real World Data (RWD), has announced a strategic refresh of its Board of Directors following its successful transition to a publicly traded entity. The company has welcomed two new board members: Jair Clarke, an Executive Advisor at World Wide Technology and CEO of Laigic, and Sherry Coonse McCraw, VP of Human Resources and former CFO of BMW North America.

Clarke's experience in AI, digital intelligence, and technology strategy is expected to contribute to market expansion, technology platform enhancement, and operational efficiency. McCraw, as the new head of the audit committee, will focus on financial oversight, transparency, and human resources leadership. This transition aims to enhance corporate governance and leverage diverse expertise to guide OneMedNet through its next growth phase.

OneMedNet (Nasdaq: ONMD), a leading curator of regulatory-grade Real World Data, has announced a follow-on private placement with an affiliate of Off the Chain Capital. The placement resulted in gross proceeds of approximately $1.7 million, following a previous $2.7 million placement with Off the Chain Capital on July 24, 2024.

The company sold 1,918,591 shares of common stock at $0.65 per share, warrants for 133,095 shares at $0.325 per share, and pre-funded warrants for 743,314 shares at $0.65 per share. OneMedNet plans to use the net proceeds for working capital and general corporate purposes, with a portion potentially used to purchase Bitcoin.

The securities were offered in a private transaction and have not been registered under the Securities Act of 1933. The company's voting agreement and registration rights agreement with Off the Chain were amended to cover the new securities issued in this placement.

OneMedNet (Nasdaq: ONMD) has received two notices from Nasdaq regarding delayed Form 10-Q filings. The first notice indicates non-compliance with Nasdaq's listing requirements due to the company's failure to file its Form 10-Q for the quarter ended June 30, 2024. The second notice grants OneMedNet an exception until October 31, 2024 to file the delinquent Forms 10-Q for both Q1 and Q2 2024.

If OneMedNet fails to regain compliance by the deadline, Nasdaq will notify the company of potential delisting, subject to appeal. OneMedNet is working with its new auditor, WithumSmith+Brown, PC, to complete and file the required documents. The company's securities continue to trade on The Nasdaq Capital Market under the symbol ONMD despite the non-compliance status.

OneMedNet (Nasdaq: ONMD), a leader in regulatory-grade Real World Data (RWD), has appointed Bob Golden as its new Chief Financial Officer. Golden, a Certified Public Accountant with over 40 years of experience, will oversee all financial and accounting operations while continuing to serve on the company's Board of Directors. He brings extensive expertise in financial strategy, business development, and mergers and acquisitions.

Golden's background includes roles as Managing Partner at Cohen, Bender & Golden LLP, and CFO positions at Promo Shop, Inc. and iKahan Media, Inc. He also serves on the Board of Directors of Talon International, Inc. This appointment comes as OneMedNet aims to advance its iRWD™ platform and expand its market presence in the global life science industry.

OneMedNet (Nasdaq: ONMD) has successfully integrated proprietary AI technology into its data curation process, revolutionizing the way healthcare data is managed. This innovation has significantly reduced operational costs and increased efficiency, allowing the company to:

• Process vast amounts of clinical data in minutes instead of hours
• Deliver longitudinal clinical data and images up to 5 times faster
• Respond to sales inquiries much quicker

The AI-driven de-identification process enhances data privacy while maintaining high-quality, regulatory-grade datasets. This advancement positions OneMedNet as a leader in Real World Data (RWD) curation, setting new standards for accuracy and speed in the healthcare data industry.

OneMedNet (Nasdaq: ONMD), a leading curator of regulatory-grade Real World Data, has announced a $4.6 million private placement with institutional investors, including affiliates of Off the Chain Capital and Discovery Capital Management. The placement closed on July 25, 2024, with the company selling shares at prices meeting Nasdaq's minimum requirements. OneMedNet plans to use the net proceeds for working capital and general corporate purposes, with $1.8 million already allocated to purchase Bitcoin. The private placement involved the sale of common stock and pre-funded warrants, with the company agreeing to file a registration statement for the resale of the issued shares and those underlying the warrants.

OneMedNet (Nasdaq: ONMD) has announced Cytel Inc. as its newest alliance partner. The partnership involves OneMedNet utilizing its iRWD™ network and platform to provide Cytel with regulatory-grade clinical data. OneMedNet's platform includes over 121 million clinical exams from more than 31 million patients across 1,400+ healthcare sites.

This collaboration will enable Cytel's customers in the biotech and pharma sectors to access ONMD's data through Cytel's Fit For Purpose Data Tool. The partnership aims to foster innovation in trial design, observational studies, and AI/ML model development, focusing on therapeutic areas such as neurologic disorders, oncology, and cardiology.